@prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "somavert is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulin like growth factor i igf i levels somavert is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulin like growth factor i igf i levels 1"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "hNL+860vbuwhpU0whPwCd5PAQWhJYpRTMfMvTVHhqvVugVA6lsCA6mSu01W9pTXaflU4/EqvAK8/zl9iSbZF0XEjs32Rq+gaChfgzPg3WJY4pL3Ct8hn5lYBVFiO5BSYGybk+terkBmpNaNZQHJXw1yzQ6zhb4hseQRIBn9WSUY="; npx:hasSignatureTarget this: . this: dct:created "2021-06-12T13:01:14.191+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }